TransThera Sciences (Nanjing) (FRA:J8J) Total Equity: €50.49 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J8J TransThera Sciences (Nanjing) Inc FRA:J8J
20 GF Score
Price €1.05
! 2 Warning Signs
View Full Analysis

What is TransThera Sciences (Nanjing) Total Equity?

TransThera Sciences (Nanjing) FRA:J8J -0.94% 20 Total Equity is €50.49 Mil as of Dec. 2025. GuruFocus rates FRA:J8J with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

TransThera Sciences (Nanjing)'s total equity for the quarter that ended in Dec. 2025 was €50.49 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

TransThera Sciences (Nanjing) Total Equity Historical Data

* Premium members only.

The historical data trend for TransThera Sciences (Nanjing)'s Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransThera Sciences (Nanjing) Total Equity Chart

TransThera Sciences (Nanjing) Annual Data
Trend Dec23 Dec24 Dec25
Total Equity
100.58 68.87 50.49

TransThera Sciences (Nanjing) Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity 100.58 0.00 68.87 70.30 50.49
FRA:J8J
20GF Score
TransThera Sciences (Nanjing) Inc FRA:J8J
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransThera Sciences (Nanjing) Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

TransThera Sciences (Nanjing)'s Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=66.192-15.706
=50.49

TransThera Sciences (Nanjing)'s Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=66.192-15.706
=50.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €50.49 Mil mean?
TransThera Sciences (Nanjing) (FRA:J8J) has a Total Equity of €50.49 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for TransThera Sciences (Nanjing) and its competitors.
Is TransThera Sciences (Nanjing)'s Total Equity too high?
TransThera Sciences (Nanjing)'s current Total Equity is €50.49 Mil. Overall, TransThera Sciences (Nanjing) has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does TransThera Sciences (Nanjing)'s Total Equity compare to VRTX and REGN?
TransThera Sciences (Nanjing)'s Total Equity of €50.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for TransThera Sciences (Nanjing) and its competitors. TransThera Sciences (Nanjing)'s current Total Equity is €50.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransThera Sciences (Nanjing) stock overvalued right now?
TransThera Sciences (Nanjing) (FRA:J8J) has a current Total Equity of €50.49 Mil. The current Total Equity is €50.49 Mil. TransThera Sciences (Nanjing)'s overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For TransThera Sciences (Nanjing) (FRA:J8J), the current Total Equity is €50.49 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransThera Sciences (Nanjing) Business Description

Other Exchanges 02617:Hong Kong
Address Biotech and Pharmaceutical Valley, 3rd floor, Building 9, Accelerator Phase 2, Jiangbei New Area, Jiangsu Province, Nanjing, CHN, 210032
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
20GF Score

Get the complete analysis for FRA:J8J

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.05
Price